Starting ART during TB therapy more than halves deaths – Durban study
In 2007, it was estimated that there were about 33 million persons living with human immunodeficiency virus (HIV) infection and 9.2 million persons with newly diagnosed tuberculosis worldwide. The two diseases are closely intertwined, and the number of patients with coinfection continues to grow rapidly. Tuberculosis is the most common opportunistic disease and the most common cause of death in patients with HIV infection in developing countries.
Notwithstanding effective tuberculosis chemotherapy, in the presence of HIV infection, tuberculosis is associated with substantially increased case fatality rates and is also the most commonly reported cause of death in South Africa. In 2007 in South Africa, an estimated 5.3 million people were infected with HIV and 341,165 with tuberculosis, of whom approximately 73% were coinfected with HIV.
The optimal timing for the initiation of antiretroviral therapy in patients with HIV and tuberculosis coinfection remains unclear. Current guidelines are based on observational studies and expert opinion. Despite World Health Organization (WHO) guidelines supporting concomitant treatment of the two diseases and urging more aggressive management, the initiation of antiretroviral therapy is often deferred until completion of tuberculosis therapy because of concern about potential drug interactions between rifampin and some classes of antiretroviral drugs, the immune reconstitution inflammatory syndrome,overlapping side effects, a high pill burden, and programmatic challenges.
This study, called the Starting Antiretroviral Therapy at Three Points in Tuberculosis (SAPIT) trial, was designed to determine the optimal time to initiate antiretroviral therapy in patients with HIV and tuberculosis coinfection who were receiving tuberculosis therapy.
See full report attached.
Author
-
Health-e News is South Africa's dedicated health news service and home to OurHealth citizen journalism. Follow us on Twitter @HealtheNews
View all posts
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Starting ART during TB therapy more than halves deaths – Durban study
by Health-e News, Health-e News
March 9, 2010